{"doi":"10.2147/vhrm.s39726","title":"The role of factor Xa inhibitors in venous thromboembolism treatment","abstract":null,"journal":"Vascular Health and Risk Management","year":2015,"id":670551,"datarank":0.5837730447165941,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.0,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":55149,"name":"Jack Ansell","orcid":"0000-0002-1237-9797","position":1,"is_corresponding":false},{"id":1751582,"name":"Katherine Cabral","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The role of factor Xa inhibitors in venous thromboembolism treatment","abstract":"Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.","is_dataset_classified":null,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25673997","pmcid":"PMC4321604","openalex_id":"https://openalex.org/W2074517603","authors":[],"funders":[],"total_grants":0,"fwci":4.8769,"citation_percentile":0.96153846,"influential_citations":0,"citation_trend":[{"year":2016,"count":6},{"year":2017,"count":4},{"year":2018,"count":7},{"year":2019,"count":5},{"year":2020,"count":3},{"year":2021,"count":4},{"year":2022,"count":5},{"year":2023,"count":3},{"year":2024,"count":6},{"year":2025,"count":5}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=23513","host_type":"journal"},{"url":"https://www.dovepress.com/getfile.php?fileID=23513","host_type":"publisher"},{"url":"https://doi.org/10.2147/vhrm.s39726","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25673997","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4321604","host_type":"repository"},{"url":"https://www.dovepress.com/the-role-of-factor-xa-inhibitors-in-venous-thromboembolism-treatment-peer-reviewed-article-VHRM","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4321604","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4321604?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Venous Thromboembolism Diagnosis and Management","Atrial Fibrillation Management and Outcomes","Blood Coagulation and Thrombosis Mechanisms","Animals","Blood Coagulation","Factor Xa Inhibitors","Hemorrhage","Humans","Morpholines","Pyrazoles","Pyridines","Pyridones","Risk Factors","Rivaroxaban","Thiazoles","Thiophenes","Treatment Outcome","Venous Thromboembolism"],"mesh_terms":["Rivaroxaban","Animals","Blood Coagulation","Hemorrhage","Humans","Morpholines","Pyrazoles","Pyridines","Pyridones","Risk Factors","Thiazoles","Thiophenes","Treatment Outcome","Venous Thromboembolism","Factor Xa Inhibitors"],"keywords":["Edoxaban","Medicine","Apixaban","Rivaroxaban","Venous thromboembolism","Intensive care medicine","Clinical trial","Dabigatran","Internal medicine","Atrial fibrillation","Warfarin","Thrombosis","Anti-xa Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"},{"sdg_number":0,"sdg_label":"Life below water"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-15T22:39:43.571798Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}